So I think those results are interesting in terms of that we will see the AMPLITUDE data tomorrow. Also like HRR deficient tumor samples that met patients, enabled patients to join the study. We will see the TALAPRO-3 data in mHSPC, which will not be at this conference, but data will be shown at a further conference. And there’s also the EvoPAR study. So a lot of studies going on with all cameras, HRR...
So I think those results are interesting in terms of that we will see the AMPLITUDE data tomorrow. Also like HRR deficient tumor samples that met patients, enabled patients to join the study. We will see the TALAPRO-3 data in mHSPC, which will not be at this conference, but data will be shown at a further conference. And there’s also the EvoPAR study. So a lot of studies going on with all cameras, HRR. HRR is differently defined within those trials. But I think that is very interesting, so that we should not focus on the BRCA1, BRCA2 only population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
